BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Stolfi C, Pellegrini R, Franzè E, Pallone F, Monteleone G. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol 2008; 14(28): 4434-4439 [PMID: 18680220 DOI: 10.3748/wjg.14.4434]
URL: https://www.wjgnet.com/1007-9327/full/v14/i28/4434.htm
Number Citing Articles
1
Joanna Słoka, Marcel Madej, Barbara Strzalka-Mrozik. Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal CancerMolecules 2023; 28(13): 5081 doi: 10.3390/molecules28135081
2
Jae Hee Cheon. Advances in Management of Intestinal Behçet’s Disease: A Perspective From GastroenterologistsJournal of Rheumatic Diseases 2021; 28(1): 4 doi: 10.4078/jrd.2021.28.1.4
3
Venkataraman Subramanian, Richard F. Logan. Chemoprevention of colorectal cancer in inflammatory bowel diseaseBest Practice & Research Clinical Gastroenterology 2011; 25(4-5): 593 doi: 10.1016/j.bpg.2011.09.003
4
Maximilian Hoffmann, Theresa A. Kant, Ramona Emig, Johanna S. E. Rausch, Manja Newe, Mario Schubert, Karolina Künzel, Luise Winter, Erik Klapproth, Rémi Peyronnet, Ursula Ravens, Ali El-Armouche, Stephan R. Künzel. Repurposing mesalazine against cardiac fibrosis in vitroNaunyn-Schmiedeberg's Archives of Pharmacology 2021; 394(3): 533 doi: 10.1007/s00210-020-01998-9
5
Rishu Dheer, Julie M. Davies, Maria T. Abreu. Intestinal Tumorigenesis2015; : 211 doi: 10.1007/978-3-319-19986-3_8
6
Reena Khanna, John K. Marshall. Crohn's Disease and Ulcerative Colitis2017; : 389 doi: 10.1007/978-3-319-33703-6_38
7
Lily P.H. Yang, Paul L. McCormack. MMX® MesalazineDrugs 2011; 71(2): 221 doi: 10.2165/11205870-000000000-00000
8
Balakrishnan S. Ramakrishna, Govind K. Makharia, Philip Abraham, Uday C. Ghoshal, Venkataraman Jayanthi, Brij Kishore Agarwal, Vineet Ahuja, Deepak K. Bhasin, Shobna J. Bhatia, Gourdas Choudhuri, Sunil Dadhich, Devendra C. Desai, Gopal Krishna Dhali, Bhaba Dev Goswami, Sanjeev K. Issar, Ajay K. Jain, Rakesh Kochhar, Ajay Kumar, Goundappa Loganathan, Sri Prakash Misra, C. Ganesh Pai, Sujoy Pal, Anna Pulimood, Amarender S. Puri, Ganesh N. Ramesh, Gautam Ray, Shivaram P. Singh, Ajit Sood, Manu Tandan. Indian Society of Gastroenterology consensus on ulcerative colitisIndian Journal of Gastroenterology 2012; 31(6): 307 doi: 10.1007/s12664-012-0259-0
9
A. LYAKHOVICH, C. GASCHE. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazineAlimentary Pharmacology & Therapeutics 2010; 31(2): 202 doi: 10.1111/j.1365-2036.2009.04195.x
10
Sung-hee Han, Jonghun Lee. Chemoprevention of Colorectal Cancer in Inflammatory Bowel DiseaseThe Korean Journal of Gastroenterology 2014; 63(1): 3 doi: 10.4166/kjg.2014.63.1.3
11
Reena Khanna, John K. Marshall. Crohn's Disease and Ulcerative Colitis2012; : 453 doi: 10.1007/978-1-4614-0998-4_36
12
Nonna Ogurchenok, Konstantin Khalin, Igor Bryukhovetskiy. Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review)Medicine International 2024; 4(3) doi: 10.3892/mi.2024.149
13
Xi Yang, Fengyi Zhang, Yajing Wang, Min Cai, Qing Wang, Qinglong Guo, Zhiyu Li, Rong Hu. Oroxylin A Inhibits Colitis-associated Carcinogenesis Through Modulating the IL-6/STAT3 Signaling PathwayInflammatory Bowel Diseases 2013; : 1 doi: 10.1097/MIB.0b013e318293c5e0
14
I. KÜBLER, M. J. KOSLOWSKI, M. GERSEMANN, K. FELLERMANN, J. BEISNER, S. BECKER, K. ROTHFUSS, K. R. HERRLINGER, E. F. STANGE, J. WEHKAMP. Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn’s diseaseAlimentary Pharmacology & Therapeutics 2009; 30(6): 621 doi: 10.1111/j.1365-2036.2009.04070.x
15
Mohab Ragab, Heidi Schlichting, Maren Hicken, Patricia Mester, Misa Hirose, Larissa N. Almeida, Lea Christiansen, Saleh Ibrahim, Hauke Christian Tews, Senad Divanovic, Christian Sina, Stefanie Derer. Azathioprine promotes intestinal epithelial cell differentiation into Paneth cells and alleviates ileal Crohn’s disease severityScientific Reports 2024; 14(1) doi: 10.1038/s41598-024-63730-4
16
Carmine Stolfi, Roberta Caruso, Eleonora Franzè, Angelamaria Rizzo, Angela Rotondi, Ivan Monteleone, Massimo Claudio Fantini, Francesco Pallone, Giovanni Monteleone. 2-Methoxy-5-Amino-N-Hydroxybenzamide Sensitizes Colon Cancer Cells to TRAIL-Induced Apoptosis by Regulating Death Receptor 5 and Survivin ExpressionMolecular Cancer Therapeutics 2011; 10(10): 1969 doi: 10.1158/1535-7163.MCT-11-0316
17
S Danese, A Mantovani. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin–Yang interplay between inflammation and cancerOncogene 2010; 29(23): 3313 doi: 10.1038/onc.2010.109
18
Ming-zhe Ma, Gang Chen, Peng Wang, Wen-hua Lu, Chao-feng Zhu, Ming Song, Jing Yang, Shijun Wen, Rui-hua Xu, Yumin Hu, Peng Huang. Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanismCancer Letters 2015; 368(1): 88 doi: 10.1016/j.canlet.2015.07.031
19
S. PARENTI, F. FERRARINI, R. ZINI, M. MONTANARI, L. LOSI, B. CANOVI, S. FERRARI, A. GRANDE. Mesalazine inhibits the β‐catenin signalling pathway acting through the upregulation of μ‐protocadherin gene in colo‐rectal cancer cellsAlimentary Pharmacology & Therapeutics 2010; 31(1): 108 doi: 10.1111/j.1365-2036.2009.04149.x
20
Shafina Siddiqui, Ankita Jaywant Deshmukh, Priyanka Mudaliar, Apoorva Jagannath Nalawade, Deepak Iyer, Jyotirmoi Aich. Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline—a reviewJournal of the Egyptian National Cancer Institute 2022; 34(1) doi: 10.1186/s43046-022-00137-0
21
Cristiana Perrotta, Paolo Pellegrino, Eliana Moroni, Clara De Palma, Davide Cervia, Piergiorgio Danelli, Emilio Clementi. Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old DrugGastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/456895
22
Shun-Wen Hsiao, Hsu-Heng Yen, Yang-Yuan Chen. Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel DiseaseGut and Liver 2022; 16(6): 840 doi: 10.5009/gnl210479
23
P. Marteau, J. Coelho. Post’U FMC-HGE2009; : 79 doi: 10.1007/978-2-287-99247-6_10
24
Song I Bae, You Sun Kim. Colon Cancer Screening and Surveillance in Inflammatory Bowel DiseaseClinical Endoscopy 2014; 47(6): 509 doi: 10.5946/ce.2014.47.6.509
25
Hyun-Young Kim, Se-Lim Kim, Young-Ran Park, Yu-Chuan Liu, Seung Young Seo, Seong Hun Kim, In Hee Kim, Seung Ok Lee, Soo Teik Lee, Sang Wook Kim. Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer CellsIntestinal Research 2015; 13(3): 233 doi: 10.5217/ir.2015.13.3.233
26
Maximilian J. Waldner, Stefan Wirtz, André Jefremow, Moritz Warntjen, Clemens Neufert, Raja Atreya, Christoph Becker, Benno Weigmann, Michael Vieth, Stefan Rose-John, Markus F. Neurath. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancerJournal of Experimental Medicine 2010; 207(13): 2855 doi: 10.1084/jem.20100438
27
Marios Efthymiou, Andrew C.F. Taylor, Michael A. Kamm. Cancer surveillance strategies in ulcerative colitisInflammatory Bowel Diseases 2011; 17(8): 1800 doi: 10.1002/ibd.21540
28
Hans Herfarth, Stephan R. Vavricka. 5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?Inflammatory Intestinal Diseases 2022; 7(1): 28 doi: 10.1159/000518865
29
Darla R. Shores, David G. Binion, Bruce A. Freeman, Paul R.S. Baker. New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel diseaseInflammatory Bowel Diseases 2011; 17(10): 2192 doi: 10.1002/ibd.21560